Igene Biotechnology Stock Net Income

Igene Biotechnology fundamentals help investors to digest information that contributes to Igene Biotechnology's financial success or failures. It also enables traders to predict the movement of Igene Pink Sheet. The fundamental analysis module provides a way to measure Igene Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Igene Biotechnology pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Igene Biotechnology Company Net Income Analysis

Igene Biotechnology's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Igene Biotechnology Net Income

    
  (140.75 K)  
Most of Igene Biotechnology's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Igene Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, Igene Biotechnology reported net income of (140,747). This is 98.83% lower than that of the Chemicals sector and 100.06% lower than that of the Materials industry. The net income for all United States stocks is 100.02% higher than that of the company.

Igene Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Igene Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Igene Biotechnology could also be used in its relative valuation, which is a method of valuing Igene Biotechnology by comparing valuation metrics of similar companies.
Igene Biotechnology is currently under evaluation in net income category among its peers.

Igene Fundamentals

About Igene Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Igene Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Igene Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Igene Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Igene Pink Sheet

Igene Biotechnology financial ratios help investors to determine whether Igene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Igene with respect to the benefits of owning Igene Biotechnology security.